Antisense Pharma completes round of financing worth approximately 8 million euro
Founding shareholders facilitate the participation of new investors

Effective July, 2011, Antisense Pharma’s founder and CEO, Dr. Karl-Hermann Schlingensiepen, will now be a member of the supervisory board and will focus on the company’s strategy as a consultant.

Regensburg, Germany July 6th, 2011. The biopharmaceutical
company Antisense Pharma announced today that MIG Funds
2, 3 and 9 as well as GAF have increased their share capital
by approximately 8 million euro. In addition, the current Chief
Execute Officer (CEO), Dr. Karl-Hermann Schlingensiepen
changed from the operative management of Antisense Pharma
to a strategic advisory position closely associated with the
company as of July 1. Dr. Karl-Hermann Schlingensiepen and
the investors developed this solution together.
Pivotal phase II/III study on pancreatic cancer: Start of a
second international clinical trial of Antisense Pharma in
preparation
“With this major entry into the systemic, intravenous
application in solid tumors, we share Antisense Pharma’s
hope that trabedersen could become the  rst medication
approved for second-line therapy of pancreatic cancer,” says
Michael Motschmann, Chief Executive of MIG Verwaltungs
AG. “Trabedersen could give new hope to patients suffering
from this extremely aggressive type of cancer and open up a
greatly needed but thus far completely vacant market niche
along with its corresponding high revenue potential. At the
same time, this means a risk reduction for the development
of trabedersen, as this medication now has several marketing
opportunities if the trials are successful. Furthermore, there is
a potential for added value since new markets can be opened
up.”
“This additional potential presents the ideal time point to further
improve Antisense Pharma’s international position,” according
to company founder Dr. Karl-Hermann Schlingensiepen. “For
this reason, we and our main investor MIG AG have decided to
increase the international pharmaceutical and capital market
experience of the company management.” In his function as
Chief Executive Of cer, Dr. Schlingensiepen has managed
several areas of the company such as preclinical research,
patents, regulatory affairs and human resources. Thanks to his
initiative, Antisense Pharma has more than 20 patent families
and holds more than 100 granted patents. During his tenure,
Antisense Pharma has been awarded the German Founders’
and the Bavarian Innovation Prizes.
“As of July of this year, I will change from my operative
management position at Antisense Pharma to a strategic
consulting function and will concentrate on giving advice on
the areas of preclinical research, patents, regulatory affairs and
representation at international congresses. My activities for
Antisense Pharma have now entered a new phase. I really look
forward to my new role as an advisor to bring our promising
medicinal product, trabedersen, to the market.” As part of
the capital increase completed on April 30, Dr. Karl-Hermann
Schlingensiepen and the other founding shareholders have
granted options which will clearly facilitate the involvement of
new and even international investors.
Dr. Heinrichs to take over as Acting CEO
Until the CEO successor is named, Dr. Hubert Heinrichs,
Managing Director and Chief Medical Of cer of Antisense
Pharma, will assume the position as Acting CEO. Dr. Heinrichs
was intensively involved in the current round of  nancing and
he has the investors’ full con dence for the management
of all commercial and scienti c areas of the company in a
competent and target-oriented manner. Dr. Heinrichs, the
entire team of Antisense Pharma and administrative board
of directors all express their sincere thanks to Dr. Karl-
Hermann Schlingensiepen for his excellent performance and
dedication to the company. “On behalf of the company I
would like to thank Dr. Schlingensiepen for his achievements
during the value-adding phase as managing director and
for the excellent and trustworthy personal cooperation,” Dr.
Heinrichs said. “At the same time I believe that the planned
partial takeover of the operative business by a new CEO with
extensive international pharmaceutical and capital market
experience carries development potential for the future tasks
that Antisense Pharma will be facing. I think that this step will
further strengthen our company, creating an ideal basis for the
company to succeed in international competition.”

About Antisense Pharma GmbH
Antisense Pharma GmbH is a biopharmaceutical company
located in Regensburg, Germany. The company focuses on
targeted therapies for previously incurable cancer diseases
and is dedicated to discovering and developing drugs based
on antisense technology for worldwide commercialization.
As a targeted therapy, the Antisense medications speci cally
block the synthesis of key cancer proteins which cause
the generation and the aggressive development of cancer
diseases. Antisense Pharma has clinical trials running that
involve patients with brain tumors, advanced pancreatic
carcinoma, malignant melanoma and colorectal carcinoma.
The company has been honored with the German Founder‘s
Award and the Bavarian Innovation Award and twice received
the Innovation Prize TOP 100.
In addition to the founding shareholders and private investors,
several venture capital funds have investing in Antisense
Pharma. The new investment has generated more than 95
million Euro of venture capital. Investors, in addition to MIG
Funds, include the Global Chance Fund, the Global Asset
Fund, the Technologie Beteiligungsgesellschaft mbH, the
Technologie Beteiligungsfonds Bayern GmbH & Co. KG and
the S-Re t AG.
About MIG Funds
The MIG Funds invest in innovative, not publicly traded
companies in the  elds of life science, biotechnology as
well as high technology. The companies have unique selling
propositions, giving them the potential to set new standards
in their respective markets. The MIG Verwaltungs AG is the
exclusive fund manager responsible for the selection and
coaching of the MIG Funds investees. In the German-speaking
area, the MIG Funds are the leading venture capital provider
for private investors. Detailed information about the investment
portfolio can be found on the Internet at www.mig-fonds.de.
For further information please contact:
Antisense Pharma GmbH
Carolin Nolte
Public Relations / Investor Relations
Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 920 13 - 175
Fax: +49 (0) 941 920 13 - 29
E-Mail: presse@antisense-pharma.com
Web: www.antisense-pharma.com
Additional Information

Publisher Contact Information:

Antisense Pharma GmbH
+49 (0) 941 920 13 - 175
presse@antisense-pharma.com

Company profile of Isarna Therapeutics (formerly Antisense Pharma)
Past press releases of Isarna Therapeutics (formerly Antisense Pharma).